We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,642

ALJ Lord Dismisses Antitrust-Based Claims In Carbon And Alloy Steel Products Investigation
  • Squire Patton Boggs
  • USA
  • November 21 2016

In May, the ITC instituted its investigation of Certain Carbon and Alloy Steel Products, Inv. No. 337-TA-1002, based on alleged violations of Section

Supreme Court Denies Cert in Lamictal Pay-For-Delay Litigation
  • Latham & Watkins LLP
  • USA
  • November 15 2016

On November 7, 2016, the Supreme Court of the United States declined to hear the petition of GlaxoSmithKline LLC (GSK), Teva Pharmaceutical Industries

Massachusetts Court Weighs in on Product Hopping Allegations and Reverse Payment Standing
  • McDermott Will & Emery
  • USA
  • November 11 2016

Addressing a motion to dismiss a bevy of antitrust allegations, the US District Court for the District of Massachusetts held that a class of

Northern District of California Dismisses Claims that Gilead Violated the Antitrust Laws in Seeking to Protect its Position on HIV Drug
  • McDermott Will & Emery
  • USA
  • November 11 2016

Ruling on a motion to dismiss, the US District Court for the Northern District of California dismissed AIDS Healthcare's antitrust claims alleging

Second Circuit: No Valid Sherman Act Claim Where Citizen Petition Denied Contemporaneously with ANDA Approval
  • McDermott Will & Emery
  • USA
  • November 11 2016

The US Court of Appeals for the Second Circuit held that a pharmaceutical manufacturer failed to state a Sherman Act Section Two claim because the

Two reverse-payment appeals to watch
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • November 10 2016

It has been over three years since the Supreme Court’s Actavis decision. Since then, numerous putative class actions alleging harm to competition as a

FTC Issues Study On Patent Assertion Entity Activity -Why Was It Silent on Competition And Can We Expect Enforcement Action?
  • Squire Patton Boggs
  • USA
  • November 2 2016

Patent assertion entities (PAEs), firms that purchase pre-existing patents and then license them for products that are already on the market, have

FTC Takes an In-Depth Look at Patent Assertion Entities
  • Weil Gotshal & Manges LLP
  • USA
  • October 26 2016

On October 6, 2016, the Federal Trade Commission released its long-awaited study on Patent Assertion Entities (“PAEs”). A PAE is an entity that

Royalties for revoked patents do not necessarily breach EU competition rules
  • Penningtons Manches LLP
  • European Union, Germany, USA
  • October 25 2016

It is hard to imagine that when Genentech signed a licence agreement in 1992 with Sanofi's predecessor, it could have foreseen the litigation storm

Antitrust competition and economic regulation quarterly newsletter - Autumn 2016
  • Hogan Lovells
  • China, European Union, Germany, Global, OECD, United Kingdom, USA
  • October 24 2016

On 20 September 2016, the Second Circuit Court of Appeals in the United States overturned a federal district court judgment in a class action